XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 07, 2023 07:30 ET
|
XOMA Corporation
Received $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter;...
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food...
XOMA Declares Quarterly Preferred Stock Dividends
September 25, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, will present a company update...
XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization Strategy
August 08, 2023 07:30 ET
|
XOMA Corporation
Completed two royalty acquisitions in the first half of 2023 adding one cash flow generating asset, one NDA-ready asset, and a Phase 2 asset Two portfolio assets are now generating cash flows from...
XOMA Added to the Russell 2000® and Russell 3000® Indexes
June 23, 2023 18:14 ET
|
XOMA Corporation
EMERYVILLE, Calif., June 23, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced it has been added to the Russell 2000® and Russell 3000® Indexes...
XOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology Asset
June 22, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the royalty and milestone rights associated with two assets from LadRx...
XOMA Declares Quarterly Preferred Stock Dividends
June 20, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to...
XOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization Strategy
May 09, 2023 07:30 ET
|
XOMA Corporation
First quarter with incoming cashflows from two commercial assets Completed first royalty asset acquisition under new leadership EMERYVILLE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- XOMA...
XOMA to Present at H.C. Wainwright BioConnect Investor Conference
April 26, 2023 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Owen Hughes, Executive Chairman, and Brad Sitko, Chief...